Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
faecalibacterium duncaniae
- Development stage
- Preclinical
- Lead developer
- BIOMNIGENE
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Faecalibacterium duncaniae is a next-generation probiotic and live biotherapeutic product (LBP) consisting of a commensal, anaerobic, butyrate-producing bacterium. Formerly classified as *Faecalibacterium prausnitzii*, it is being developed for the treatment of inflammatory and infectious diseases, including inflammatory bowel disease (IBD), colitis, and acute viral respiratory infections like influenza. The bacterium exerts its therapeutic effects through the production of short-chain fatty acids (SCFAs), specifically butyrate, and the microbial anti-inflammatory molecule (MAM) protein. These metabolites modulate the gut-lung axis and SCFA-interferon pathways to reduce systemic inflammation and viral load. Research also suggests potential in preventing the atopic march, a progression from allergic skin inflammation (atopic dermatitis) to respiratory involvement (asthma).
- Other names
- Faecalibacterium prausnitzii
02
Targets
FFAR2TJP1 (Tight junction protein 1 (ZO-1))HCAR2 (Hydroxycarboxylic acid receptor 2)
Beyond the preview
Go deeper on faecalibacterium duncaniae.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on faecalibacterium duncaniae.